# COCP catalysts: Cocrystal Pharma, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cocp/catalysts

> Cocrystal Pharma, Inc. (COCP) has no upcoming catalysts in this calendar. The latest recorded is the CDI-988 topline data readout, Q4 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for COCP?

Cocrystal Pharma, Inc. (COCP) has no upcoming catalysts in this calendar. The latest recorded is the CDI-988 topline data readout, Q4 2026. Press release filed with the SEC (EX-99): ""We expect to report topline data from our Phase 1b norovirus trial by the end of the fourth quarter of 2026, and we're grateful for OPKO's continued conviction in the value of our lead asset, CDI-988, and our broader antiviral pipeline spanning influenza, coronaviruses and hepatitis C."" [Calendar and source filings](https://sec-api.dev/companies/cocp/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001493152-26-035743, https://www.sec.gov/Archives/edgar/data/1412486/000149315226035743/ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-08-03. Cite: https://sec-api.dev/companies/cocp/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Cocrystal Pharma, Inc. |
| Ticker | COCP (Nasdaq) |
| SEC CIK | 1412486 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/cocp |

## Cash runway

Cash $7.0M as of 2025-12-31; quarterly burn $1.7M; about 12.1 months of runway at that rate (XBRL company facts, accession 0001493152-26-013838).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2023 | [CC-42344 trial start](https://sec-api.dev/pdufa/cc-42344) | COCP |  | completed | "December 2023 we began a randomized, double-blind, placebo-controlled Phase 2a human challenge study to evaluate the safety, tolerability, and viral and clinical measurements of CC-42344 in influenza A-infected subjects in the United Kingdom, following authorization from the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315226013837/ex99-1.htm)) |
| late 2024 | [CDI-988 topline data readout](https://sec-api.dev/pdufa/cdi-988) | COCP |  | scheduled | ""The multiple-ascending dose portion in our Phase 1 pan-norovirus/pan-coronavirus study with oral protease inhibitor CDI-988 is underway and we are on track to report topline results in late 2024 or early 2025," he added." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/ex99-1.htm)) |
| Sep 2024 | [CDI-988 trial start](https://sec-api.dev/pdufa/cdi-988) | COCP |  | completed | "September 2024 we initiated dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1412486/000149315226037573/form10-q.htm)) |
| late 2024 | [CC-42344 topline data readout](https://sec-api.dev/pdufa/cc-42344) | COCP |  | scheduled | ""In the Phase 2a influenza A challenge study with our oral PB2 inhibitor CC-42344, we expect to report topline results before year end." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/ex99-1.htm)) |
| November 13, 2024 | [Cocrystal Pharma, Inc. earnings report](https://sec-api.dev/companies/cocp/catalysts) | COCP |  | completed | "Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/ex99-1.htm)) |
| Dec 2024 | [CC-42344 trial start](https://sec-api.dev/pdufa/cc-42344) | COCP |  | completed | "The Company initiated the Phase 2a human challenge study in December 2024 following authorization from the MHRA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315224052600/ex99-1.htm)) |
| 1H 2025 | [Cocrystal Pharma, Inc. topline data readout](https://sec-api.dev/companies/cocp/catalysts) | COCP |  | scheduled | "The topline data of the MAD cohorts, including based on an additional cohort with a higher dose of 1200 mg and a shorter treatment duration of five consecutive days, is expected to be released in the first half of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1412486/000164117225001496/form10-k.htm)) |
| March 31, 2025 | [Cocrystal Pharma, Inc. earnings report](https://sec-api.dev/companies/cocp/catalysts) | COCP |  | completed | "Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000164117225001494/ex99-1.htm)) |
| Q2 2025 | [CDI-988 topline data readout](https://sec-api.dev/pdufa/cdi-988) | COCP |  | scheduled | "o We expect to report topline oral CDI-988 Phase 1 results from the high-dose healthy subject cohort in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000164117225010537/ex99-1.htm)) |
| May 15, 2025 | [Cocrystal Pharma, Inc. earnings report](https://sec-api.dev/companies/cocp/catalysts) | COCP |  | completed | "- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company") reports financial results for the three months ended March 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000164117225010537/ex99-1.htm)) |
| August 14, 2025 | [Cocrystal Pharma, Inc. earnings report](https://sec-api.dev/companies/cocp/catalysts) | COCP |  | completed | "Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000164117225023727/ex99-1.htm)) |
| November 14, 2025 | [Cocrystal Pharma, Inc. earnings report](https://sec-api.dev/companies/cocp/catalysts) | COCP |  | completed | "Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315225022603/ex99-1.htm)) |
| Q1 2026 | [CDI-988 trial start](https://sec-api.dev/pdufa/cdi-988) | COCP |  | scheduled | "Expects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315225022603/ex99-1.htm)) |
| March 9, 2026 | [CDI-988 trial start](https://sec-api.dev/pdufa/cdi-988) | COCP |  | completed | "announces the first subjects have been dosed in a Phase 1b norovirus challenge study (NCT07198139) to evaluate CDI-988 as both a preventive and treatment for norovirus infections." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315226009309/ex99-1.htm)) |
| March 31, 2026 | [Cocrystal Pharma, Inc. earnings report](https://sec-api.dev/companies/cocp/catalysts) | COCP |  | completed | "Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315226013837/ex99-1.htm)) |
| Q4 2026 | [CDI-988 topline data readout](https://sec-api.dev/pdufa/cdi-988) | COCP |  | scheduled | ""We expect to report topline data from our Phase 1b norovirus trial by the end of the fourth quarter of 2026, and we're grateful for OPKO's continued conviction in the value of our lead asset, CDI-988, and our broader antiviral pipeline spanning influenza, coronaviruses and hepatitis C."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315226035743/ex99-1.htm)) |

## Drugs

- [CC-42344](https://sec-api.dev/pdufa/cc-42344): 
- [CDI-988](https://sec-api.dev/pdufa/cdi-988): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cocp/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "COCP catalysts: Cocrystal Pharma, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cocp/catalysts

```bibtex
@misc{secapidev_companies_cocp_catalysts_20261116,
  title        = {COCP catalysts: Cocrystal Pharma, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cocp/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cocp_catalysts_20261116","title":"COCP catalysts: Cocrystal Pharma, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cocp/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
